Bullish Options Activity in Gilead Sciences (GILD) Post Earnings Announcement -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Gilead Sciences (GILD) PT Raised to $76 at BMO Capital Following 1Q
May 3, 2017 9:17 AM EDTBMO Capital raised its price target on Gilead Sciences (NASDAQ: GILD) to $76.00 (from $75.00) while maintaining a Market Perform rating. GILD reported 1Q revenues of $6.5bn, below the Street's estimates of $6.62bn, as continued strength from HIV could not off-set further deterioration in HCV.
GILD... More
Gilead Sciences (GILD): Bright Spots Among The Misses - Stifel
May 3, 2017 8:21 AM EDTStifel analyst, Katherine Breedis, reiterated her Buy rating on shares of Gilead Sciences (NASDAQ: GILD) after the company reported results that missed Street expectations on the top and bottom line.
Despite the weak results, the analyst believes the market is not... More
Gilead Sciences (GILD): Quiet 1Q17 Earnings - Baird
May 3, 2017 8:13 AM EDTBaird analyst, Brian Skorney, reiterated his Outperform rating on shares of Gilead Sciences (NASDAQ: GILD) after the company reported less than stellar numbers but overall trends in HCV and HIV as expected.
The analyst believes Gilead's story is shifting back... More
Gilead Sciences (GILD) Declares $0.52 Quarterly Dividend; 3% Yield
May 2, 2017 4:03 PM EDTGilead Sciences (NASDAQ: GILD) declared a quarterly dividend of $0.52 per share, or $2.08 annualized.
The dividend will be payable on June 29, 2017, to stockholders of record on June 16, 2017, with an ex-dividend date of June 14, 2017.
The annual yield on the dividend is 3... More
Gilead Sciences (GILD) Misses Q1 EPS by 5c; Reiterates Full Year 2017 Guidance
May 2, 2017 4:02 PM EDTGilead Sciences (NASDAQ: GILD) reported Q1 EPS of $2.23, $0.05 worse than the analyst estimate of $2.28. Revenue for the quarter came in at $6.505 billion versus the consensus estimate of $6.62 billion.
Reiterates Full Year 2017 Guidance
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
... More